Key Positives From The Results
Royalty income maintained double-digit growth at JPY 1,228M (+14.4% YoY), with tegoprazan's H1 sales in Korea reaching KRW 120B (+15.4% YoY), demonstrating solid momentum. In addition, a third-party allotment from HK inno.N (approx. JPY 1.4B) strengthened the financial base, while two new out-licensing agreements underscored the crystallization of pipeline value.
- Tegoprazan Korea sales grew +15.4% YoY, maintaining the #1 position with a 15% share of the peptic ulcer therapeutics market. In April 2026, the product achieved the top-ranked monthly outpatient prescription sales among all pharmaceuticals
- U.S. Phase III trial (TRIUMpH-EE) results announced, confirming statistically significant superiority over PPIs in healing and maintenance rates for severe EE. Under FDA review with approval expected in January 2027
- Out-licensed a 5-HT₄ agonist and a motilin receptor agonist to the Lazarus group, establishing a new scheme to advance development using external funding without deploying internal capital
- Operating cash flow turned positive at +JPY 613M vs. negative JPY 242M in the year-ago period, driven by receivables collection. Cash and equivalents expanded to JPY 4,696M (+44.8%)
- Equity ratio improved to 70.6% (+5.5pp vs. prior FY-end), benefiting from the third-party allotment and debt repayment
Key Concerns From The Results
Business revenue came in at JPY 1,455M (−5.2% YoY), a top-line decline. Other income comprising milestones and upfront payments halved to JPY 227M (−50.9% YoY), making it clear that achieving the full-year plan is structurally dependent on event-driven revenue recognition in H2.
- Full-year guidance achievement rate for business revenue stands at just 36.6%, requiring JPY 2,525M (63.4% of the total) to be booked in H2. Timing uncertainty around milestones and upfront payments remains elevated
- Operating loss widened by JPY 148M to negative JPY 338M (vs. negative JPY 190M in the year-ago period). R&D expenses of JPY 861M (+10.1% YoY) and SG&A of JPY 592M (+6.9% YoY) continued to rise
- EBITDA swung to negative JPY 112M (vs. positive JPY 46M in the year-ago period). Ongoing goodwill amortization of JPY 139M continues to weigh on profitability
- Income taxes of JPY 140M (vs. JPY 63M in the year-ago period) drove the interim net loss to negative JPY 466M
- Share price has declined −46.9% YTD, significantly underperforming market benchmarks, highlighting challenges in translating enterprise value into market valuation
Focus Areas / Items To Monitor Going Forward
- Progress of tegoprazan's FDA review and timing of approval (expected January 2027). U.S. launch represents an inflection point for royalty growth and is pivotal to the feasibility of HK inno.N's target of KRW 3T in global sales by 2030
- Specific scale and certainty of milestones and upfront payments expected in H2. Achieving the full-year operating income forecast of JPY 165M requires over JPY 503M in H2 operating income (to offset the interim loss of negative JPY 338M), making the probability of event-driven revenue the central focus
- Progress and out-licensing timing of Fimecs' TPD (targeted protein degradation) pipeline. Clinical development readiness of the IRAK-M degrader and materialization of collaborative research outcomes with Astellas Pharma will be key indicators of medium- to long-term growth potential
- Quantitative explanation of the number and probability of milestones and upfront payments expected in H2
- Qualitative guidance on post-approval royalty levels for tegoprazan in the U.S.
- Funding status and development initiation timeline for Lazarus group out-licensing deals (Giathera / Giovel)
- Progress and expected timeline for ghrelin receptor agonist out-licensing activities
- Specific milestones for Fimecs' IRAK-M degrader clinical development preparation
- Expected timeline for generating development candidates from the joint research with HK inno.N in the metabolic/endocrine disease area
- Key assumptions underlying impairment risk assessment for goodwill (approx. JPY 3.56B)
- Full-year R&D expense outlook and management's view on investment efficiency
- Whether any changes have been made to the assumptions underlying the three-year business revenue outlook of JPY 12.8B
- Measures to address share price decline (status of share buyback considerations, IR enhancement initiatives)
Key Financial Highlights
| Item | Value | YoY |
|---|---|---|
| Business Revenue | JPY 1,455M | −5.2% |
| └ Royalty Income | JPY 1,228M | +14.4% |
| └ Other Income | JPY 227M | −50.9% |
| Operating Income | −JPY 338M | - |
| Recurring Profit | −JPY 326M | - |
| Net Income Attributable to Owners of Parent Company (Interim) | −JPY 466M | - |
| EPS | −JPY 18.10 | - |
| EBITDA | −JPY 112M | - |
| Comprehensive Income | −JPY 497M | - |
| Total Business Expenses | JPY 1,794M | +3.9% |
| └ Cost of Business | JPY 339M | −12.7% |
| └ R&D Expenses | JPY 861M | +10.1% |
| └ SG&A | JPY 592M | +6.9% |
The year-ago period recorded an operating loss of negative JPY 190M, a recurring loss of negative JPY 291M, and an interim net loss of negative JPY 354M — all loss figures have widened. While royalty income grew steadily, the decline in business revenue was driven by milestones and upfront payments slipping into H2.
Performance By Business Segment
The group discloses "pharmaceutical R&D" as a single segment, with no sub-segment P&L breakdown available. The revenue structure is bifurcated into royalty income (recurring income from marketed products) and other income (event-driven revenue such as milestones, upfront payments, and research collaboration fees). Royalty income comprises human pharmaceutical tegoprazan (K-CAB®) and three animal health products (GALLIPRANT®, ENTYCE™, ELURA™), growing a stable +14.4% YoY.
Segment Performance Table
| Segment | Revenue | YoY | Operating Income | YoY | Margin |
|---|---|---|---|---|---|
| Pharmaceutical R&D (Consolidated) | JPY 1,455M | −5.2% | −JPY 338M | - | - |
- Royalty Income: JPY 1,228M (+14.4% YoY). Driven by tegoprazan's +15.4% YoY sales growth in Korea. Sales footprint expanded to 20 countries, with the product achieving #1 P-CAB sales in China and adding an NSAID-induced ulcer prevention indication in Korea (6 approved indications, the most in its class)
- Animal Health: GALLIPRANT® (canine osteoarthritis treatment) continues to sustain blockbuster-level sales (annual revenue exceeding JPY 10B). ENTYCE™ and ELURA™ remain stable
- Other Income (Milestones, Upfront Payments, etc.): JPY 227M (−50.9% YoY). Milestone and upfront payment revenues underpinning the full-year plan were not recognized in H1, with the deferral to H2 serving as the primary driver of the overall revenue decline
Progress Versus Full-Year Guidance
The full-year guidance achievement rate for business revenue stands at 36.6%, a low level, though the company describes progress as "in line with the initial plan." The prior fiscal year (FY2025/12) showed a similar pattern, with H1 business revenue achieving 38.6% (1,535/3,979) of the full-year total, reflecting the typical revenue structure where milestones and upfront payments are heavily weighted toward H2. Achieving the full-year operating income target of JPY 165M requires JPY 503M in H2 operating income, making the timing of event-driven revenue recognition the key variable.
| Item | Value (H1 Cumulative) | Full-Year Forecast | Progress Rate |
|---|---|---|---|
| Business Revenue | JPY 1,455M | JPY 3,980M | 36.6% |
| Operating Income | −JPY 338M | JPY 165M | - |
| Recurring Profit | −JPY 326M | JPY 86M | - |
| Net Income | −JPY 466M | −JPY 63M | - |
- Event-driven revenue from milestones and upfront payments tends to concentrate in H2 (particularly Q4). In the prior fiscal year, other income totaled JPY 1,737M, accounting for approximately 44% of full-year business revenue
- Royalty income tends to be recognized on a stable quarterly basis
Changes To Guidance
No revision to guidance. The full-year consolidated earnings forecast published on February 13, 2026 has been maintained. Milestones and upfront payments not recognized in H1 are expected to be booked in H2.
Commentary On Shareholder Returns
The FY2026/12 dividend forecast remains at JPY 0.00 per share (no dividend). The company plans to initiate shareholder dividends in line with the strengthening of its financial base, and will consider share buybacks on a flexible basis.
Financial Position
The equity ratio improved to 70.6% (+5.5pp vs. prior FY-end), driven by an increase in share capital and capital surplus from the third-party allotment (approx. JPY 1.4B) and debt repayment. Cash and equivalents rose to JPY 4,696M, up +44.8% vs. prior FY-end, providing ample liquidity.
- Key Figures
- Leverage Metrics
| Item | Value | Additional Information |
|---|---|---|
| Cash and Cash Equivalents | JPY 4,696M | +44.8% vs. prior FY-end |
| Total Assets | JPY 11,006M | +4.7% vs. prior FY-end |
| └ Total Current Assets | JPY 6,190M | +8.9% vs. prior FY-end |
| └ Total Non-Current Assets | JPY 4,816M | −0.3% vs. prior FY-end |
| Net Assets | JPY 7,830M | +13.6% vs. prior FY-end |
| Goodwill | JPY 3,560M | −3.8% vs. prior FY-end (JPY 139M amortization) |
| Total Interest-Bearing Debt | JPY 2,685M | Current portion 512 + Long-term borrowings 1,882 + Lease obligations 290 |
| └ Long-Term Borrowings (incl. current portion) | JPY 2,395M | −JPY 256M vs. prior FY-end |
| └ Lease Obligations | JPY 290M | +JPY 40M vs. prior FY-end |
| Shareholders' Equity | JPY 7,775M | +13.5% vs. prior FY-end |
| EBITDA | −JPY 112M | Company-disclosed figure |
News Released Alongside The Earnings Announcement
None
Major Announcements During The Quarter
- 2026/07/30Consolidated subsidiary Fimecs received a U.S. patent allowance for its IRAK-M degrader (FIM-001), strengthening its IP foundation Notice Regarding U.S. Patent Allowance for Fimecs' IRAK-M Protein Degrader (Heterocyclic Compound)
- 2026/07/27Tegoprazan received approval for the additional indication of "prevention of NSAID-induced ulcers" in Korea, reaching 6 approved indications — the most in its class Notice Regarding Additional Indication Approval for Gastric Acid Secretion Inhibitor Tegoprazan in Korea
- 2026/06/12Entered into out-licensing agreements with Lazarus group affiliates for a 5-HT₄ agonist and a motilin receptor agonist, establishing a new external-funding-based business creation model Notice Regarding Out-Licensing Agreements with Lazarus Pharmaceuticals, LLC Group Under a New Business Creation Model
- 2026/06/02Entered into a joint research agreement with RIKEN on computational chemistry and AI-driven drug discovery support technology Notice Regarding Joint Research Agreement with RIKEN — Development of Drug Discovery Support Technology Integrating Computational Chemistry and Experimental Data
- 2026/05/20U.S.-based Velovia Pharma exercised its option rights for an animal health license; the company received the option exercise fee Notice Regarding Receipt of Upfront Payment in Connection with Option Exercise by Velovia Pharma, LLC
Large-Shareholding Filings / Material Proposals Over The Past Year
- HK inno.N Corporation: 10.60% → 15.94% (2026/01/29) — Strategic investment for the purpose of a capital and business alliance. Acquired 1,555,900 shares through third-party allotment
- Yuichi Kakinuma (co-holder): 9.75% → 9.17% (2026/01/29) — Stable shareholder with long-term holding intent. Change in co-holder aggregate reflects HK inno.N's acquisition (20.35% → 25.11%)
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.